Additional file 1 of MiR-151a: a robust endogenous control for normalizing small extracellular vesicle cargo in human cancer
Creators: name: Burdiel, Miranda
name: Jiménez, Julia
name: Rodríguez-Antolín, Carlos
name: García-Guede, Álvaro
name: Pernía, Olga
name: Sastre-Perona, Ana
name: Rosas-Alonso, Rocío
name: Colmenarejo, Julián
name: Rodríguez-Jiménez, Carmen
name: Diestro, María Dolores
name: Martínez-Marín, Virginia
name: Higueras, Oliver
name: Cruz, Patricia
name: Losantos-García, Itsaso
name: Peinado, Héctor
name: Vera, Olga
name: de Castro, Javier
name: Ibáñez de Cáceres, Inmaculada
Publisher: name: figshare
Year: 2023
Subjects: subject: Biophysics
subject: Biochemistry
subject: Medicine
subject: Cell Biology
subject: Genetics
subject: FOS: Biological sciences
subject: Molecular Biology
subject: Physiology
subject: Pharmacology
subject: Biotechnology
subject: Chemical Sciences not elsewhere classified
subject: Developmental Biology
subject: Cancer

description: Additional file 1: Figure S1. Characterization of sEVs derived from human cancer cell lines, plasma samples and ascitic fluid. Figure S2. Cell viability after treatment with platinum-based drugs such as cisplatin (CDDP) and carboplatin (CBDCA). Figure S3. Amplification cycles of endogenous sEV-miRNAs in human cancer cell lines. Figure S4. Correlation between miR-151a-3p amplification cycle in sEVs isolated from the secretome of H1299, A2780, MCF7 and SW780 cell lines culture in the presence of either sEVs-depleted FBS (X axis) or absence of FBS (Y axis). Figure S5. Amplification cycles of endogenous sEV-miRNAs in 30 human samples. Figure S6. miR-151a-3p cycle amplification in the sEVs isolated from human samples. Figure S7. miR-151a-3p cycle amplification in the sEVs isolated from the second validation cohort of human samples. Table S1. Raw CT values of miR-151a-3p, miR-22-5p, miR-221-3p, miR-16-5p, miR-451a and their normalized levels using all the endogenous miRNAs in the sEVs compartment from human cancer cell lines and 293T. Table S2. Raw CT values of the endogenous miRNAs in sEVs compartment from 41M cells treated with radiotherapy at 0, 2, 4 and 6 Gy. Table S3. Raw CT values of miR-151a-3p, miR-22-5p, miR-221-3p, miR-16-5p, miR-451a and its normalized levels using all the endogenous miRNAs in circulating sEVs from 14 NSCLC patients (nine advanced and five early stage), six ovarian cancer patients (three plasma and three paired ascitic fluid), five glioblastoma patients and five healthy volunteers. Table S4. Raw CT values of miR-151a-3p, miR-22-5p, miR-221-3p, miR-16-5p, miR-451a and its normalized levels using all the endogenous miRNAs in circulating sEVs from 79 NSCLC patients (51 advanced and 28 early stage). Table S5. Raw CT values of miR-151a-3p, miR-22-5p, miR-221-3p, miR-16-5p, miR-451a and its normalized levels using all the endogenous miRNAs in circulating sEVs from 35 ovarian cancer patients. Table S6. Raw CT values of miR-151a-3p, miR-22-5p, miR-221-3p, miR-16-5p, miR-451a and its normalized levels using all the endogenous miRNAs in circulating sEVs from 12 glioblastoma patients and 13 healthy volunteers. Table S7. Cell line authentication using GenePrintR10 kit (Promega, USA). Genomics Service of the iiBm CSIC-UAM.